Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Adage Capital Management
AddedFeb 13, 2024
UpdatedJul 16, 2026
Adage Capital Management

Adage Capital Management

Operating

Adage Capital Management: Expert S&P 500 asset management for endowments and foundations.

Location
Boston, MA, US
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Adage Capital Management is a money management firm specializing in S&P 500 asset management, primarily for endowments and foundations. The firm typically invests in later-stage rounds, including Series B, C, D, and beyond, as well as post-IPO equity and private equity. Their investment focus spans various sectors, with a notable presence in the biotechnology and pharmaceutical industries.

Notable portfolio companies include Abeona Therapeutics, Antios Therapeutics, AppDynamics, and GitLab. Key partners or decision-makers at Adage Capital Management are not publicly detailed, but the firm is known for its expertise in managing substantial assets for institutional clients. Adage offers unique value-add services such as tailored investment strategies and extensive market analysis to support the growth and success of its portfolio companies.

Adage Capital Management - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments54
Current Portfolio Count41
Total Portfolio Exits3

Top Investment Stages

Series B13 (31.7%)
Post Ipo Equity10 (24.4%)
Series D7 (17.1%)
Series C6 (14.6%)
Series Unknown5 (12.2%)

Stage Mix

Series B 32%Post Ipo Equity 24%Series D 17%Series C 15%Series Unknown 12%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Astria Therapeutics logo

Astria Therapeutics

Syros Pharmaceuticals logo

Syros Pharmaceuticals

Arvinas logo

Arvinas

Soleno Therapeutics logo

Soleno Therapeutics

Benitec Biopharma logo

Benitec Biopharma

HawkEye 360 logo

HawkEye 360

Karyopharm Therapeutics logo

Karyopharm Therapeutics

Abeona Therapeutics logo

Abeona Therapeutics

Harness logo

Harness

Menlo Microsystems logo

Menlo Microsystems

Antios Therapeutics logo

Antios Therapeutics

Pyramid Biosciences logo

Pyramid Biosciences

Gopuff logo

Gopuff

Goat Group logo

Goat Group

Imaginab logo

Imaginab

Forter logo

Forter

Stem logo

Stem

Arch Oncology logo

Arch Oncology

ViaCyte logo

ViaCyte

Rapid Micro Biosystems logo

Rapid Micro Biosystems

Flywire logo

Flywire

Caribou Biosciences logo

Caribou Biosciences

Silence Therapeutics logo

Silence Therapeutics

HemoShear Therapeutics logo

HemoShear Therapeutics

Werewolf Therapeutics logo

Werewolf Therapeutics

Adage Capital Management - Classification

Also Known As
  • Adage Capital Management, L.P.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end